Author/Authors :
Packer، نويسنده , , Leisl M. and Rana، نويسنده , , Sareena and Hayward، نويسنده , , Robert and OʹHare، نويسنده , , Thomas R. Eide، نويسنده , , Christopher A. and Rebocho، نويسنده , , Ana and Heidorn، نويسنده , , Sonja and Zabriskie، نويسنده , , Matthew S. and Niculescu-Duvaz، نويسنده , , Ion and Druker، نويسنده , , Brian J. and Springer، نويسنده , , Caroline and Marais، نويسنده , , Richard، نويسنده ,
Abstract :
Summary
w that imatinib, nilotinib, and dasatinib possess weak off-target activity against RAF and, therefore, drive paradoxical activation of BRAF and CRAF in a RAS-dependent manner. Critically, because RAS is activated by BCR-ABL, in drug-resistant chronic myeloid leukemia (CML) cells, RAS activity persists in the presence of these drugs, driving paradoxical activation of BRAF, CRAF, MEK, and ERK, and leading to an unexpected dependency on the pathway. Consequently, nilotinib synergizes with MEK inhibitors to kill drug-resistant CML cells and block tumor growth in mice. Thus, we show that imatinib, nilotinib, and dasatinib drive paradoxical RAF/MEK/ERK pathway activation and have uncovered a synthetic lethal interaction that can be used to kill drug-resistant CML cells in vitro and in vivo.
